Bladder Cancer Coverage from Every Angle


PD-L1 Expression: Predicting Immunotherapy Response in Urothelial Carcinoma
Researchers Construct Prognostic Nomogram for Use in Patients With Bladder Cancer and Lung Metastasis
Can BCG Vaccination Induce Immune Responses Against COVID-19?
Finding Genetic Clues in Cats, Dogs, and Cows to Treat Human Bladder Cancer
The Changing Treatment Landscape in Urothelial Carcinoma: Focus on PARP Inhibitors
Surgical Strategies to Reduce Recurrence of Upper Tract Urothelial Carcinoma
Can the Antidepressant Fluoxetine Promote Sensitivity to Cisplatin in Bladder Cancer?
Researchers Explore How Sexual Diversity May Impact Bladder Cancer
Effects of Multiple Risk Factors on Cancer-Specific Survival in Non–Muscle-Invasive Bladder Cancer
ASCOBT 2023: Nectin-4 Expression and the Tumor Microenvironment in Bladder Cancer
$11.2 Million Grant From NCI to Fund Research on Sex Differences in Bladder Cancer
ASCOBT 2023: Predicting Immunotherapy Responses With VI-RADS Scores in Muscle-Invasive Bladder Cancer
Ongoing Trial to Evaluate Erdafitinib in FGFR3-Mutated Non–Muscle-Invasive Bladder Cancer
Efficacy of Pembrolizumab Monotherapy and Histologic Subtype of Advanced Urothelial Cancer
Comparing the Cost of Robot-Assisted Versus Open Radical Cystectomy for Bladder Cancer
Long-Term Outcomes With Pembrolizumab Plus Chemoradiotherapy in Urothelial Bladder Cancer
Advanced Bladder Cancer: Combination Therapy of Copanlisib and Avelumab Focus of Phase II Trial
Can Personalized Whole-Genome Sequencing Identify MRD Rates in Muscle-Invasive Bladder Cancer?
Does CDH1 Mutation Status Affect Treatment Efficacy in Urothelial Bladder Cancer?
Durability of Complete Responses in Patients Treated With Pembrolizumab for Advanced Urothelial Cancer
Long-Term Safety Analyses of Maintenance Avelumab From JAVELIN Bladder 100
Do Survival Outcomes Vary Between Micropapillary and Classic Urothelial Cancers?
ASCO 2023: Comparing Types of Lymphadenectomy in Surgical Treatment of Muscle-Invasive Urothelial Cancer
ASCO 2023: Phase III Trial Offers Insights on Prevalence of FGFR3 Alterations in Invasive Urothelial Cancer
ASCO 2023: IMvigor130 Trial Update With Atezolizumab Plus Chemotherapy for Metastatic Urothelial Cancer
ASCO 2023: Some Patients With Metastatic Urothelial Cancer May Benefit From Erdafitinib Over Chemotherapy
ASCO 2023: 5-Year Survival Data on Perioperative Chemotherapy in Muscle-Invasive Bladder Cancer
ASCO 2023: How Many Cycles of Neoadjuvant Chemotherapy Is Enough for Muscle-Invasive Bladder Cancer?
ASCO 2023: Final NORSE Trial Results on Erdafitinib Plus Cetrelimab in Metastatic Urothelial Carcinoma
ASCO 2023: Long-Term Update on Use of Enfortumab Vedotin Plus Pembrolizumab in Advanced Urothelial Carcinoma
ASCO 2023: Factors Affecting Recurrence of Bladder Cancer After Transurethral Resection
CT Analysis of Inflammatory Myofibroblastic Bladder Tumors
What Can Optimizing Surveillance Protocols Do for Patients With Bladder Cancer?
BCG After Transurethral Resection of Bladder Cancer: How Body Composition May Impact Outcomes
Investigational Chemotherapy Delivery System Advances Treatment of BCG-Unresponsive Bladder Cancer
Around the World, Early Recurrence of Bladder Cancer Differs After Transurethral Resection
Oncolytic Vaccine Plus Pembrolizumab for BCG-Unresponsive Bladder Cancer
USC Surgeons Take Steps Toward the First-in-Human Bladder Transplantation
AUA 2023: Does Prior Radiation Therapy Impact BCG Outcomes in High-Risk, Bladder Cancer?
AUA 2023: Reducing Urinary Tract Infections After Flexible Cystoscopy
Using Molecular Subtyping to Predict Response to Immunotherapy in Urothelial Cancer
Novel Gene Signature for Bladder Cancer: Predicting Prognosis and Therapeutic Response
AACR 2023: Biomarkers May Predict Response to Neoadjuvant Chemotherapy in Bladder Cancer
AACR 2023: IHC Subtypes Offer Prognostic Hint in Muscle-Invasive Bladder Cancer
NCCN 2023: Update on Emerging Therapies for Bladder Cancer
AACR 2023: Is a Cell-Free DNA Assay Clinically Effective in Urothelial Carcinoma?
Lysosomal Positioning in Bladder Cancer With Hyperactivated Transcription Factor EB
Use of Noncoding Mutation Hotspots as a Noninvasive Tool for Bladder Cancer Detection
FDA Brief: Antibody-Drug Conjugate and PD-1 Inhibitor Combination Granted Accelerated Approval in Advanced Urothelial Cancer
Sequential HER2-Targeted Antibody-Drug Conjugate in Resistant Metastatic Bladder Cancer: Case Study
PRR11 Expression in Bladder Urothelial Carcinoma: Prognostic and Therapeutic Implications

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.